"El Hospital Universitario Quirónsalud Madrid se ha convertido en un referente de la sanidad de la Comunidad de Madrid. Profesionales de primer nivel, alta tecnología y atención personalizada son los tres pilares que sustentan su atención sanitaria. Cuenta con 54.000 metros cuadradados de superficie hospitalaria donde se ofrece atención a 39 especialidades médico-quirúrgicas, lo que lo convierte en un hospital general que es capaz de ofrecer respuesta a todas las necesidades que requieran los pacientes. A sus instalaciones, hay que sumar un Servicio de Urgencias 24 horas."

During the past decade, Hospital Universitario Quironsalud Madrid conducted 159 clinical trials. In the 10-year time frame, 159 clinical trials started and 35 clinical trials were completed, i.e. on average, 22% percent of trials that started reached the finish line to date. In the past 5 years, 95 clinical trials started and 27 clinical trials were completed. i.e. 28.4% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Hospital Universitario Quironsalud Madrid" #1 sponsor was "Janssen Research & Development, LLC" with 18 trials, followed by "Eli Lilly and Company" with 15 trials sponsored, "Boehringer Ingelheim" with 8 trials sponsored, "Incyte Corporation" with 8 trials sponsored and "Pfizer" with 8 trials sponsored. Other sponsors include 120 different institutions and companies that sponsored additional 88 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Hospital Universitario Quironsalud Madrid" #1 collaborator was "Apices Soluciones S.L." with 4 trials as a collaborator, "Dynamic Science S.L." with 3 trials as a collaborator, "Pfizer" with 3 trials as a collaborator, "UNICANCER" with 3 trials as a collaborator and "Bayer" with 2 trials as a collaborator. Other collaborators include 80 different institutions and companies that were collaborators in the rest 84 trials.

According to Clinical.Site data, the most researched conditions in "Hospital Universitario Quironsalud Madrid" are "Multiple Myeloma" (10 trials), "Breast Cancer" (7 trials), "Idiopathic Pulmonary Fibrosis" (7 trials), "Carcinoma, Non-Small-Cell Lung" (5 trials) and "Breast Neoplasms" (4 trials). Many other conditions were trialed in "Hospital Universitario Quironsalud Madrid" in a lesser frequency.

Most popular intervention types in "Hospital Universitario Quironsalud Madrid" are "Drug" (136 trials), "Other" (13 trials), "Biological" (11 trials), "Device" (8 trials) and "Procedure" (5 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (40 trials), "Lenalidomide" (7 trials), "Bortezomib" (6 trials), "Dexamethasone" (6 trials) and "Pembrolizumab" (6 trials). Other intervention names were less common.

The vast majority of trials in "Hospital Universitario Quironsalud Madrid" are 153 trials for "All" genders, 19 trials for "Female" genders and 10 trials for "Male" genders.

Currently, there are 91 active trials in "Hospital Universitario Quironsalud Madrid". 1 are not yet recruiting, 48 are recruiting, 41 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 65 completed trials in Hospital Universitario Quironsalud Madrid, undefined suspended trials, and 16 terminated clinical trials to date.

Out of the total trials that were conducted in Hospital Universitario Quironsalud Madrid, 21 "Phase 1" clinical trials were conducted, 51 "Phase 2" clinical trials and 68 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 6 trials, and there were also 9 trials that are defined as “Not Applicable".